key: cord-0744420-hrxq9qz0
authors: Beinvogl, Beate; Cohen, Alexandra; DiFilippo, Courtney; Kane, Madeline; Nurko, Samuel; Rosen, Rachel
title: IMPACT OF CORONAVIRUS DISEASE 2019 on THE PEDIATRIC AERODIGESTIVE POPULATION
date: 2021-12-20
journal: J Pediatr
DOI: 10.1016/j.jpeds.2021.12.022
sha: a35a83a7640885111a250b2c75052c3ad8f8d3fe
doc_id: 744420
cord_uid: hrxq9qz0

OBJECTIVE: To determine the impact of the (COVID-19) quarantine on baseline health, medication use, health anxiety, and healthcare utilization in pediatric aerodigestive patients, and to evaluate for associations of commonly prescribed medications with risk of COVID-19 illness. STUDY DESIGN: Prospective study of patients presenting in-person to pediatric neurogastroenterology clinics between July 2020 and March 2021. RESULTS: Of 202 recruited patients, 71.3% were seen in aerodigestive diseases center and 28.7% in the Functional Abdominal Pain (FAP)/Motility clinic. Of all patients, 25.1% reported improved overall health during quarantine; ADC patients (35.3%) report improved overall health compared with the FAP/Motility patients (3.6%, p=0.0001). ADC patients had less airway symptoms (p<0.05) and less medication use during quarantine (inhaled steroids, p<0.05 and albuterol, p<0.05). Despite objective improvement, there was significant health related anxiety with higher anxiety scores reported during and at the end of quarantine (p<0.05), with no difference between patient groups (p>0.11). Patients continued to access healthcare during quarantine. 28.7% of patients were seen in the emergency room (FAP patients more than ADC patients, p =0.02) and 19.8% were hospitalized. COVID-19 testing was performed in 58.4% of patients and 2.0% (n=4) of the entire cohort tested positive. CONCLUSION: ADC patients show improvement of airway symptoms and decreased use of medications during the pandemic, despite increased health-related anxiety. Despite complexities of accessing care due to the widespread lockdown, all patient groups continued to access healthcare.

Conclusion ADC patients show improvement of airway symptoms and decreased use of medications during the pandemic, despite increased health-related anxiety. Despite complexities of accessing care due to the widespread lockdown, all patient groups continued to access healthcare.

In response to the emergence of the Coronavirus disease 2019 (COVID-19) pandemic in early 2020, large areas of the United States were placed under lockdown to slow down and prevent further spread of the SARS-CoV2 virus. In addition to its major impact on daily life and risks to health, this also affected access to care for patients both due to decreased availability and fear of exposure to the virus. [1] [2] [3] Pediatric patients with aerodigestive disorders were felt to be among the greatest risk of severe disease from the virus because of the risk of infection on lung health [4] , but no publications exist studying exactly how these patients have been affected.

The goal of this study was to better understand how the COVID-19 pandemic quarantine impacted ADC patients and to better understand their risks for COVID- 19 . The aims of this study were ( to understand the impact of the pandemic on baseline health and health-related anxiety in ADC patients; to determine the impact of COVID-19 on healthcare utilization; and to determine if any commonly prescribed gastrointestinal medications were associated with testing positive for COVID-19.

This is a prospective questionnaire study of consecutive patients seen in-person in the ADC, Functional Abdominal Pain (FAP) or Motility clinic at a tertiary care hospital during the SARS-CoV2 pandemic between July 2020, after the clinics reopened, and March 2021. All patients presenting for in-person outpatient appointments to all three clinics were given questionnaire to reduce risk of bias. Patients presenting for virtual visits were excluded from the analysis because the original goal of the questionnaire was to assess for parental concerns related to in person health care concerns and the feasibility of in person clinics.

Patients/families were surveyed about demographics, comorbidities, baseline airway and gastrointestinal, medication use, risk factors for exposure to and testing for SARS-CoV-2, health care utilization and health-related anxiety (rated on a Likert scale 0-10, with 0 representing no and 10 representing most severe anxiety) before and during the pandemic. Patients were considered positive for COVID-19 if they tested positive by polymerase chain reaction testing. If a question was not answered, it was considered negative. This study was part of a prospective quality initiative whose aim was to determine health care utilization to understand clinical needs.

Statistical analyse: Values are expressed as mean and standard deviation. Means were compared using t-tests. Proportions were compared using Chi Square analyses or McNemar test for related samples. Statistical analysis was performed using SPSS Version 27.

Of the 202subjects participatingin this study, 144 (71%) were seen in aerodigestive diseases center, 37 (18.3%) in motility clinic and 21 (10.4%) in the functional abdominal pain (FAP) clinic. Surveys were completed by parents in 91% of cases and by patients themselves in 9% a J o u r n a l P r e -p r o o f mean of 7.7±1.6 months (range 4 -11 months) into the quarantine. Baseline characteristics are detailed in Table I . Patients seen in aerodigestive diseases center were younger, more likely to be male, have aspiration and feeding tube dependency. Otherwise, there was no difference in baseline characteristics or comorbidities (Table I) .

When comparing presence of selected symptoms before and during the quarantine period, there was a decreased incidence of airway symptoms across all patients during the quarantine period compared with before, including wheezing (p<0.01), chronic cough (p<0.01) and pneumonia (p=0.04). ( Figure 1 , A) Change in overall health status during quarantine compared with before (unchanged, improved, or worse) are detailed in Table I . Of note, 27 patients were born during quarantine and unable to answer this question and therefore not included in the analysis. Although most patients reported no change in their overall health status, there were notably higher reports of subjective improvement in the ADC group (35.3%) compared with the FAP/Motility group (3.6%) (p=0.0001), and notably higher rates of worsening of overall health in the FAP/Motility group (32.1%) compared with the ADC group (7.5%, p=0.001, Table I ).

From a medication perspective, there was a significant decrease in utilization of inhaled steroids during the pandemic among all patients (p<0.05, Figure 1 , B). , of patients receiving inhaled steroids before the quarantine (n=55), 12/55 (21.8%) discontinued steroids, and only 3/147 (2.0%) of patients were newly started during quarantine.

Anxiety scores (0-10) increased significantly during quarantine (p<0.05) compared with before and remained high through the end of quarantine. There was no difference in anxiety scores between the ADC and FAP/Motility groups at any timepoint ( Figure 2 ).

Despite complexities of accessing care due to the widespread lockdown, all patient groups continued to access healthcare. Fifty-eight of 202 (28.7%) patients were seen in the emergency room (ER), notably FAP/Motility patients presented to the ER more frequently than ADC patients (41.4% compared with 22.9%) (p=0.02), however the number of outpatient visits per month during the study period were similar between groups (p=0.43). Forty of 202 (19.8%), were hospitalized during the study period with no difference in hospitalization rates between the ADC and FAP/Motility groups (p=0.56). Of all patients, 84/202 (41.6%) saw their primary care physician for an in-person visit and 61/202 (30.2%) for a virtual visit at one point during the quarantine study period, with no significant difference in the visits per month between the groups for both in-person visits (p=0.43) or virtual visits (p=0.87) during the study period. The most common reasons for seeking care are summarized in Figure 3 , A-C. There was no significant difference in health care utilization between families with higher (anxiety score >5) and lower (anxiety score ≤5) anxiety scores (p>0.05). We investigated if there was an association between medication usage and likelihood of contracting COVID-19. All four patients who were COVIDpositive were taking PPIs at the time of testing. The use of PPIs (p=0.01) and inhaled steroids (p=0.04) were associated with testing positive for COVID-19 (Table II ; available at www.jpeds.com).

There were no significant associations with COVID-19 illness and race (p=0.37), geographics (p=0.07), living with siblings under age 18 years (p=0.55), having in-home (p=0.57) or out of home childcare (p=0.56), comorbidities (neurologic (p=0.33), cardiac (p=0.65), genetic (p=0.22), presence of aspiration (p=0.23), or presence of a feeding tube (p=0.21).

. We show that respiratory symptoms improved, and that use of airway medication used decreased in ADC patients during quarantine with no change in gastrointestinal symptoms. We found increased overall health-related anxiety regardless of patient cohort during and at the end of, compared with before, the quarantine period. Though limited by the small number of patients who were COVID-19 positive , we show an association of current PPI and inhaled steroid use with COVID-19 positivity.

Our study shows that respiratory symptoms including wheezing, chronic cough, and pneumonia decreased significantly during quarantine among the ADC cohort. This is not surprising given the higher rate of chronic respiratory symptoms in this population, the likelihood that patients were home-bound in the setting of the quarantine, and the pervasive mask usage particularly in the Northeast of the United States. Our results are supported by other pediatric studies showing improved asthma control with decreased asthma exacerbations during the lockdown [5, 6] . Overall improvement of health during quarantine was reported in 26% of all patients, with a higher proportion of improvement among the ADC group (37%) compared with the FAP/Motility group (3.7%), also reflecting the likely beneficial effect of having less environmental triggers for respiratory symptoms in the ADC group.

About one third (31.0%) of FAP/Motility patients experienced symptom exacerbation.

These exacerbations may be due to social isolation, less opportunities to utilize coping strategies such as distraction, and limited access to care including psychological services that occurred as the pandemic continued. This contrasts with finding that patients with disorders of the gut-brain J o u r n a l P r e -p r o o f interaction, such as Irritable Bowel Syndrome (IBS) showed that 57% had significant improvement of all symptoms during the early quarantine period [7] .

We also found that health anxiety was high during the pandemic, a finding that is consistent across other studies [8, 9] . We show no difference in anxiety between patients with aerodigestive conditions versus functional gastrointestinal and motility disorders. It is possible that the reasons for increased anxiety were different between the ADC and FAP/Motility populations. This may be due to the overall increase in health-related anxiety across the population due to having any chronic condition [4] , or the increase in underlying comorbid anxiety as frequently seen in patients with IBS [10] . this study concluded in March 2021, prior to the COVID-19 vaccine availability to the general public or teenagers, which may have played a role in persistently high levels of anxiety.

Of the four patients who had COVID-19 infections, none were hospitalized. Symptoms of COVID-19 included typically cough, fever, nasal congestion, as reported [11] . Early in the pandemic, chronic pulmonary disease was considered a risk factor for severe disease, though more recent studies have suggested that it does not increase morbidity or mortality related to COVID-19 [5, 12] . We also did not detect a statistically significant difference in the incidence of when compared with those not taking PPIs [13] . , Our findings suggest that acid suppression may increase the risk of viral infections, though this will require larger studies to confirm [14- J o u r n a l P r e -p r o o f 20]. This concept of increased infection risk with acid suppression use is not novel. the PPIinduced risk of bacterial pulmonary infections is thought to be related to bacterial dysbiosis, local mucosal secretory alterations and anti-inflammatory effects of PPIs [14, 21] . In aerodigestive patients in whom aspiration is particularly common, the alteration of the gastric microorganisms with PPI use may be particularly concerning [22] . Although studies on acid suppression and SARS-CoV-2 are conflicting, adult data suggests that low gastric pH ≤3 impairs the infectivity of a similar SARS coronavirus 1, compared with higher gastric pH's which did not inactivate the virus [23] . This may be relevant for COVID-19 because SARS-CoV-2 is known to enter the body via both the respiratory and gastrointestinal systems [13, 24, 25] . A meta-analysis of 8 studies published by Yan et al found no difference in risk of COVID-19 infection in adult patients on or off PPI therapy, but suggested that PPIs may have a role in progression to severe disease and secondary infections [13, [26] [27] [28] [29] [30] .

We also found that receiving inhaled corticosteroids during the pandemic was associated with COVID-19 positivity, although again our data is limited given the small number of patients who were COVID-19 positive in this cohort. If the findings are confirmed in a larger studies, it would reinforce the recommendations not to use steroids unless patients are symptomatic with COVID-19 and requiring supplemental oxygen [31] [32] [33] . Insymptomatic patients, steroids have been shown to reduce coronavirus replication, reduce risk of acute respiratory distress syndrome), and improve pulmonary function testing [34] [35] [36] [37] [38] [39] . prior studies show that ICS increase the risk of pneumonia and lower respiratory infections in adults with asthma [40] . In vitro studies have suggested that steroids can impair antiviral innate immune responses [41, 42] and that ICS use may lead to delayed virus clearance [43] [44] . Little is known age, sex, comorbidities, residence and other medication use [45] . In contrast, a study of Korean adults showed only a 1.6% prevalence of ICS use among those who tested positive for COVID-19

with no significant association of ICS use and clinical outcomes [46] . Finally, a recent metaanalysis showed no increase for severe COVID-19 disease, arguing that it is safe to continue ICS use to control underlying disease [47] .

There are several limitations to our small study without a healthy control group. We intended to determine the impact of COVID-19 on ADC patients, so we chose two multidisciplinary clinics that deal with chronic neurogastroenterology diseases at a tertiary care center . Not unexpectedly the ADC group, which has a higher prevalence of respiratory symptoms, were younger, which presents another limitation to the comparison. the number of patients who tested positive for COVID-19 was low which limits the power of this study, but even with low numbers, we still found significant associations. our findings indicate the need for larger studies to evaluate the effect of medications on COVID-19 infection risk or viral illnesses in general. The low observed rate of positivity for COVID-19 among our cohort may be due to the study having been conducted early in the pandemic, with limited testing availability; or due to the strict quarantine measures, whereby children with chronic illness were especially sheltered J o u r n a l P r e -p r o o f during this time. Although we know the testing rates were high in our population, we do not know why patients were tested. Finally, the health-related anxiety levels may be an underestimate because all patients were recruited during an in-person visit, which may present a subset with less severe underlying medical conditions or less patient/parental anxiety and therefore more willing to come for a clinic visit rather than meet via telemedicine.

In conclusion, the COVID-19 pandemic has had a significant impact on pediatric ADC patients. Although about half of patients had no change to their overall health status, one third experienced overall improved health, including a decrease of respiratory symptoms. The rate of COVID-19 positivity was low in this study cohort, but all affected patients had a mild disease course and recovered fully. There was a significant increase in overall health-related anxiety reported by patients during and at the end compared with before the quarantine period. 

Delayed access or provision of care in Italy resulting from fear of COVID-19. The Lancet

Provision of Pediatric Immunization Services During the COVID-19 Pandemic: an Assessment of Capacity Among Pediatric Immunization Providers Participating in the Vaccines for Children Program -United States

COVID-19 related reduction in pediatric emergency healthcare utilization -a concerning trend

Updated diagnosis, treatment and prevention of COVID-19 in children: experts' consensus statement (condensed version of the second edition)

Asthma and COVID-19: An early inpatient and outpatient experience at a US children's hospital

Reduced pediatric urgent asthma utilization and exacerbations during the COVID-19 pandemic

Overall Impact of COVID-19 Outbreak in Children with Functional Abdominal Pain Disorders: Results From the First Pandemic Phase

Impact of COVID-19 on the mental health of US college students

Post-lockdown depression and anxiety in the USA during the COVID-19 pandemic

Healthcare spending and utilization for pediatric Irritable Bowel Syndrome in a commercially insured population

Coronavirus disease 2019 (COVID-19) in children and/or adolescents: a meta-analysis

Management of chronic pulmonary disease in the time of coronavirus disease 2019

Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. The American journal of gastroenterology

Side Effects and Complications of Proton Pump Inhibitors: A Pediatric Perspective

Proton pump inhibitors: Risks of long-term use

The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association

Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study

Acid-Suppressing Agents and Risk for Clostridium difficile Infection in Pediatric Patients

Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children

Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis

Changes in Gastric and Lung Microflora With Acid Suppression: Acid Suppression and Bacterial Growth

16S Community Profiling Identifies Proton Pump Inhibitor Related Differences in Gastric, Lung, and Oropharyngeal Microflora

Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV

Potential Causes and Consequences of Gastrointestinal Disorders during a SARS-CoV-2 Infection

Evidence for Gastrointestinal Infection of SARS-CoV-2

Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis

Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching

Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor? Journal of internal medicine

ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy

Will Proton Pump Inhibitors Lead to a Higher Risk of COVID-19 Infection and Progression to Severe Disease? A Meta-analysis

Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with

Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective

A comprehensive review on potential therapeutics interventions for COVID-19

The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells

Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells

Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome

Inhalation therapies in acute respiratory distress syndrome

Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case-control study

Budesonide and formoterol reduce early innate anti-viral immune responses in vitro

Reduced Antiviral Interferon Production in Poorly Controlled Asthma Is Associated With Neutrophilic Inflammation and High-Dose Inhaled Corticosteroids

Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations

Increased type 2 inflammation post rhinovirus infection in patients with moderate asthma

Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona

Inhaled Corticosteroids and COVID-19 Risk and Mortality: A Nationwide Cohort Study

Preadmission use of inhaled corticosteroids and risk of fatal or severe COVID-19: a meta-analysis

COVID-19 positive; Med+: patient on medication before/during quarantine; Med-: patient NOT on medication before/during quarantine